Leveraging Naturally Assembled Tumor Extracellular Vesicles as Self-Adjuvanting Nanovaccines to Potentiate Cancer Immunotherapy via cGAS/STING Activation - PubMed
3 days ago
- #nanovaccines
- #cGAS/STING pathway
- #cancer immunotherapy
- The cGAS/STING pathway activation is a promising strategy for cancer immunotherapy but faces challenges like poor pharmacological properties and side effects.
- Tumor-derived extracellular vesicles (EVs) are used to create a self-adjuvanting nanovaccine, enriching double-stranded DNA (dsDNA) to enhance antigen presentation and T-cell activation.
- Metformin-loaded nanoparticles (Met-PC-NPs) increase reactive oxygen species (ROS) in tumor cells, leading to the production of EVs containing dsDNA and tumor antigens (Met-PC-EVs).
- Met-PC-EVs migrate to lymph nodes, activate antigen-presenting cells, and promote CD8+ T-cell responses, resulting in tumor eradication and long-term immune memory.
- Combining Met-PC-EVs with immune checkpoint inhibitors shows a synergistic effect, offering a clinically translatable approach for EV-based cancer vaccines.